Letter Concerning “Enzyme Replacement Therapy in a Patient With Fabry Disease and the Development of IgE Antibodies Against Agalsidase Beta but Not Agalsidase Alpha”, by Tanaka Et Al.

Journal of Inherited Metabolic Disease - Netherlands
doi 10.1007/s10545-010-9219-y
Full Text
Abstract

Available in full text

Categories
Genetics
Date
Authors
Publisher

Wiley

Related search

Psy23 - Agalsidase Alfa and Agalsidase Beta for Treatment of Fabry Disease

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Biventricular Cardiomyopathy Improvement by Shifting Therapy From Agalsidase Alfa to Agalsidase Beta in Anderson-Fabry Disease (RCD Code: III-3B.2)

Journal of Rare Cardiovascular Diseases
Cardiovascular MedicineCardiology
2018English

Comparison of the Effects of Agalsidase Alfa and Agalsidase Beta on Cultured Human Fabry Fibroblasts and Fabry Mice

Journal of Human Genetics
Genetics
2005English

Sustained, Long-Term Renal Stabilization After 54 Months of Agalsidase Beta Therapy in Patients With Fabry Disease

Journal of the American Society of Nephrology : JASN
MedicineNephrology
2007English

Clinical Course of Patients With Fabry Disease Who Were Switched From Agalsidase-Β to Agalsidase-Α

Genetics in Medicine
MedicineGenetics
2014English

Effects of Enzyme Replacement Therapy and Antidrug Antibodies in Patients With Fabry Disease

Journal of the American Society of Nephrology : JASN
MedicineNephrology
2018English

The Effectiveness of Long-Term Agalsidase Alfa Therapy in the Treatment of Fabry Nephropathy

Clinical Journal of the American Society of Nephrology
EpidemiologyNephrologyCritical CareTransplantationIntensive Care Medicine
2012English

Long-Term Dose-Dependent Agalsidase Effects on Kidney Histology in Fabry Disease

Clinical Journal of the American Society of Nephrology
EpidemiologyNephrologyCritical CareTransplantationIntensive Care Medicine
2017English

Renal Aspects and Enzyme Replacement Therapy of Fabry Disease

2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy